139 related articles for article (PubMed ID: 11354305)
21. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
22. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
Lanes SF; Lanza LL; Radensky PW; Yood RA; Meenan RF; Walker AM; Dreyer NA
Arthritis Rheum; 1997 Aug; 40(8):1475-81. PubMed ID: 9259428
[TBL] [Abstract][Full Text] [Related]
23. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
24. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Mora C; González A; Díaz J; Quintana G
Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
[TBL] [Abstract][Full Text] [Related]
25. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
Blanco FJ; Ballina J; Carbonell J; Martín-Mola E; Tornero J; Ramírez E; Galván J
Reumatol Clin; 2011; 7(2):88-93. PubMed ID: 21794790
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
27. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
28. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Aletaha D; Smolen JS
Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
[TBL] [Abstract][Full Text] [Related]
29. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
30. Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients.
Jin XM; Lee J; Choi NK; Seong JM; Shin JY; Kim YJ; Kim MS; Yang BR; Park BJ
J Korean Med Sci; 2014 Feb; 29(2):210-6. PubMed ID: 24550647
[TBL] [Abstract][Full Text] [Related]
31. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.
Schmajuk G; Trivedi AN; Solomon DH; Yelin E; Trupin L; Chakravarty EF; Yazdany J
JAMA; 2011 Feb; 305(5):480-6. PubMed ID: 21285425
[TBL] [Abstract][Full Text] [Related]
32. Challenges in assessing costs of rheumatoid arthritis.
Harrison MJ
Case Manager; 2003; 14(5):65-72; quiz 73. PubMed ID: 14593350
[No Abstract] [Full Text] [Related]
33. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
34. [Approximation to the cost of pharmacological treatment of rheumatoid arthritis in Spain].
Mera Varela A; Blanco Rodríguez J; Caamaño Freire M
An Med Interna; 2003 Mar; 20(3):114-21. PubMed ID: 12756895
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.
Tosh JC; Wailoo AJ; Scott DL; Deighton CM
J Rheumatol; 2011 Aug; 38(8):1593-600. PubMed ID: 21572149
[TBL] [Abstract][Full Text] [Related]
36. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
37. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
[TBL] [Abstract][Full Text] [Related]
38. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
[TBL] [Abstract][Full Text] [Related]
39. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
